Search Results - "Bahlis, N.J"

P32 MAJESTEC‐1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B‐CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) by Donk, N., Cortes‐Selva, D., Casneuf, T., Vishwamitra, D., Stein, S., Perova, T., Ramos, E., Van Steenbergen, L., Boominathan, R., Lau, O., Davis, C., Banerjee, A., Stephenson, T., Uhlar, C., Kobos, R., Goldberg, J., Pei, L., Trancucci, D., Girgis, S., Lin, S.X.W., Wu, L.S., Moreau, P., Usmani, S., Bahlis, N.J., Verona, R.

Get full text

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE‐CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA‐3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL by Rodríguez‐Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel‐Hartmann, A., Yang, Z., Favre‐Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.

Get full text

IMiDs induced Ikaros-dependent downregulation of MYC in myeloma is mediated through the repression of the 3’ IGH enhancer activity and the NURD complex repositioning by Neri, P, Tagoug, I, Simms, J, Maity, R, Zepeda, V, Duggan, P, Bahlis, N.J

Get full text

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the upfront therapy of transplant ineligible patients with multiple myeloma by Venner, C.P, Bahlis, N.J, Neri P, P, Sandhu, I, Duggan, P, Belch, A.R, Hewitt, J.D, Pilarski, L.M, Nikitina, T, Jimenez-Zepeda, V

Get full text

Evaluation of HCT-CI Comorbidity Scores and Allogeneic Transplant Outcome of Young Adults After Myeloablative Conditioning with Fludarabine and Busulfan +/- TBI Malignancies by Slaby, J, Williamson, T, Chaudhry, A.M, Larratt, L, Turner, R.A, Bahlis, N.J, Brown, C.B, Daly, A, Duggan, P, Geddes, M, Quinlan, D, Savoie, M.L, Shafey, M, Storek, J, Yue, P, Zacarias, N, Stewart, D.A, Russell, J.A, Russell, J

Get full text

Patterns Of Chronic Graft-Vs-Host Disease And Associated Mortality After Myeloablative Conditioning Incorporating Fludarabine, Busulfan And ATG by Zakaria, M.Z, Yang, M, Larrat, L, Turner, R, Brown, C, Bahlis, N.J, Savoie, L, Daly, A, Geddes, M, Storek, J, Zacarias, N, Duggan, P, Quilan, D, Stewart, D.A, Russell, J.A

Get full text

Influence Of Comorbidities On Transplant Outcomes In Patients Aged 50 Years Or More After Myeloablative Conditioning Incorporating Fludarabine, Busulfan And ATG by Elkourashy, S.A, Yang, M, Turner, R, Larratt, L.M, Brown, C.B, Bahlis, N.J, Savoie, L.M, Daly, A, Geddes, M, Storek, J, Zacarias, N, Duggan, P.R, Quinlan, D, Stewart, D, Russell, J.A

Get full text

PF631 HEALTH‐RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW‐DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT by Reece, D., Bahlis, N.J., Samaras, C., Sebag, M., Berdeja, J., Ganguly, S., Matous, J., Song, K., Seet, C.S., Talamo, G., Acosta‐Rivera, M., Bar, M., Quick, D., Anz, B., Fonseca, G., Agarwal, A., Chung, W., Zafar, F., Siegel, D.S.

“…Background: Treatment of relapsed refractory multiple myeloma (RRMM) is complex and requires evaluation of disease and patient factors to maximize efficacy and…”
Get full text

PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D‐RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK by Dimopoulos, M.A., San‐Miguel, J., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P.J., Kim, K., Takezako, N., Moreau, P., Sutherland, H.J., Magen, H., Iida, S., Kim, J.S., Prince, H.M., Cochrane, T., Oriol, A., Bahlis, N.J., Chari, A., O’Rourke, L., Trivedi, S., Casneuf, T., Chiu, C., Soong, D., Ukropec, J., Qi, M., Avet‐Loiseau, H., Usmani, S.Z., Kaufman, J.L.

“…Background: High‐risk cytogenetic abnormalities confer poor outcomes in patients (pts) with MM. In POLLUX, D‐Rd demonstrated significant clinical benefit,…”
Get full text

PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D‐RD) VS RD: MAIA by Perrot, A., Facon, T., Plesner, T., Usmani, S.Z., Kumar, S., Orlowski, R.Z., Bahlis, N.J., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Chaleteix, C., Araujo, C., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., Wang, J., Kobos, R., McKay, C., Gries, K.S., Trudeau, J., Hulin, C., Weisel, K.

“…Background: MAIA, an ongoing phase 3 trial of transplant‐ineligible patients with NDMM, demonstrated significant improvement in progression‐free survival with…”
Get full text

DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX) by Bahlis, N.J., Moreau, P., Nahi, H., Plesner, T., Goldschmidt, H., Suzuki, K., Orlowski, R.Z., Rabin, N., Leiba, M., Oriol, A., Chari, A., San Miguel, J., Richardson, P.G., Usmani, S., O'Rourke, L., Wu, K., Casneuf, T., Chiu, C., Qin, X., Dimopoulos, M.A.

Get full text

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG by El Kourashy, S, Williamson, T, Chaudhry, M A, Savoie, M L, Turner, A R, Larratt, L, Storek, J, Bahlis, N J, Brown, C B, Yang, M, Quinlan, D, Geddes, M, Zacarias, N, Daly, A, Duggan, P, Stewart, D A, Russell, J A

“…Non-myeloablative (MA) and reduced intensity allo-SCT regimens are offered to older patients and/or those with comorbidities because the morbidity and…”
Get full text